Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 1997

View Archived Issues

Focus on Alzheimer's disease research in the U.S.

Focus on diabetes research in the U.S.

Drug discovery technology pioneered at Oncogene Science now patented

Essential tremor gene located by Icelandic genomics company

Annual Report: Daiichi Pharmaceutical

Heparinase gene covered by U.S., European patents

Gliatech cleared to begin U.S. clinical trials of third ADCON product

Regressin induces apoptosis and direct inhibition of tumor cell growth

T Cell Sciences recipient of SBIR grant to develop atherosclerosis model

Clinical studies begin with BNP-7787

Biricodar dicitrate enters phase II studies in ovarian cancer

RWJ-63556: dual COX-2/5-LO inhibitor effective in canine model of local inflammation

Vertex, Kissei to collaborate on MAP kinase inhibitors

New clinical study on Multikine initiated in Canada

L-374087: a new thrombin inhibitor developed at Merck & Co.

HER-2/neu gene amplification useful in predicting outcome in endometrial cancer

DuPont Merck presents dual MMP/TNF-alpha-converting enzyme inhibitor

Myocardial protective effects of Hoe-642 evaluated in porcine hearts

Sano's combination patch shows promise for smoking cessation

Clinical results reported for protease inhibitor/nucleoside analogue combination

Kampo medicine with hypolipidemic and antiatherosclerotic effects

In vitro and in vivo antibacterial activity of two herbal medicines

Capases: a new target for neurodegenerative disease therapy

Cannabinoid receptor ligand shows synergistic hematopoietic effects in vitro

Pivotal data reported for ENBREL in severe RA

New trinem reported by SRI

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...